Michel Detheux - 09 Mar 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
09 Mar 2023
Net transactions value
$0
Form type
4
Filing time
10 Mar 2023, 18:51:36 UTC
Previous filing
10 Mar 2023
Next filing
07 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +346,000 $0.000000 346,000 09 Mar 2023 Common Stock 346,000 $16.66 Direct F1
transaction ITOS Stock Option (Right to Buy) Gift $0 -254,997 -74% $0.000000 91,003 09 Mar 2023 Common Stock 254,997 $16.66 Direct F1, F2
transaction ITOS Stock Option (Right to Buy) Gift $0 +254,997 $0.000000 254,997 09 Mar 2023 Common Stock 254,997 $16.66 By MG3A F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.
F2 The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.